Syros Pharmaceuticals Financials

Syros Pharmaceuticals Stock Summary

Syros Pharmaceuticals competes with Surrozen, Bolt Biotherapeutics, Larimar Therapeutics, Keros Therapeutics, and Kezar Life. Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts. Syros Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 124 people.

Syros Pharmaceuticals Key Financial Ratios

There are many critical financial ratios that Syros Pharmaceuticals' investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Syros Pharmaceuticals reports annually and quarterly.

Syros Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Syros Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Syros Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Syros Pharmaceuticals competition to find correlations between indicators driving Syros Pharmaceuticals's intrinsic value. More Info.Syros Pharmaceuticals is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Syros Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Syros Pharmaceuticals Systematic Risk

Along with financial statement analysis, the daily predictive indicators of Syros Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Syros Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Syros Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Syros Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Syros Pharmaceuticals's daily price indicators and compare them against related drivers.

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Syros Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

If you are still planning to invest in Syros Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Syros Pharmaceuticals' history and understand the potential risks before investing.